121 related articles for article (PubMed ID: 38286117)
1. Varying impact of lenvatinib or sorafenib therapy on skeletal muscle loss in patients with hepatocellular carcinoma.
Yamauchi Y; Saeki I; Fujisawa K; Egusa M; Nishiyama N; Fujioka T; Kawamoto D; Sasaki R; Nishimura T; Tanabe N; Hisanaga T; Matsumoto T; Ishikawa T; Yamasaki T; Takami T
Oncology; 2024 Jan; ():. PubMed ID: 38286117
[TBL] [Abstract][Full Text] [Related]
2. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients.
Uchikawa S; Kawaoka T; Namba M; Kodama K; Ohya K; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Chayama K; Aikata H
Liver Cancer; 2020 Apr; 9(2):148-155. PubMed ID: 32399429
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib.
Uojima H; Chuma M; Tanaka Y; Hidaka H; Nakazawa T; Iwabuchi S; Kobayashi S; Hattori N; Ogushi K; Morimoto M; Kagawa T; Tanaka K; Kako M; Koizumi W
Liver Cancer; 2020 Apr; 9(2):193-206. PubMed ID: 32399433
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
5. Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
Imai K; Takai K; Hanai T; Ideta T; Miyazaki T; Kochi T; Suetsugu A; Shiraki M; Shimizu M
Int J Mol Sci; 2015 Apr; 16(5):9612-24. PubMed ID: 25927582
[TBL] [Abstract][Full Text] [Related]
6. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma.
Saeki I; Yamasaki T; Maeda M; Kawano R; Hisanaga T; Iwamoto T; Matsumoto T; Hidaka I; Ishikawa T; Takami T; Sakaida I
Liver Cancer; 2018 Oct; 7(4):359-371. PubMed ID: 30488024
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis.
Guan J; Yang Q; Chen C; Wang G; Zhu H
EXCLI J; 2021; 20():1-16. PubMed ID: 33510588
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of lenvatinib
Jaiswal V; Hameed M; Naz S; Roy P; Deb N; Ukrani J; Krishna Mohan GV; Taha AM; Huang H; Kumar V; Vachhani B; Attia AM; Nath SD; Solimn MA; Mukherjee D
JGH Open; 2023 Dec; 7(12):832-840. PubMed ID: 38162860
[TBL] [Abstract][Full Text] [Related]
9. Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
Naganuma A; Hoshino T; Suzuki Y; Uehara D; Kudo T; Ishihara H; Sato K; Kakizaki S; Yamada M; Takagi H
Acta Med Okayama; 2017 Aug; 71(4):291-299. PubMed ID: 28824184
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib or Sorafenib Treatment Causing a Decrease in Skeletal Muscle Mass, an Independent Prognostic Factor in Hepatocellular Carcinoma: A Survival Analysis Using Time-Varying Covariates.
Imai K; Takai K; Unome S; Miwa T; Hanai T; Suetsugu A; Shimizu M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686497
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.
Terashima T; Yamashita T; Takata N; Takeda Y; Kido H; Iida N; Kitahara M; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2021 Feb; 51(2):190-200. PubMed ID: 33197087
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
13. Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Endo K; Kuroda H; Kanazawa J; Sato T; Fujiwara Y; Abe T; Sato H; Kooka Y; Oikawa T; Sawara K; Takikawa Y
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32756366
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis.
Luo J; Gao B; Lin Z; Fan H; Ma W; Yu D; Yang Q; Tian J; Yang X; Li B
Front Oncol; 2022; 12():1010726. PubMed ID: 36620586
[TBL] [Abstract][Full Text] [Related]
16. Real-World Lenvatinib
Kuo YH; Lu SN; Chen YY; Kee KM; Yen YH; Hung CH; Hu TH; Chen CH; Wang JH
Front Oncol; 2021; 11():737767. PubMed ID: 34760699
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
18. Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.
Fukushima T; Morimoto M; Ueno M; Kubota K; Uojima H; Hidaka H; Chuma M; Numata K; Tsuruya K; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Yamamoto K; Tanaka K; Maeda S
JGH Open; 2022 Jan; 6(1):29-35. PubMed ID: 35071785
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population.
Lee SW; Yang SS; Lien HC; Peng YC; Ko CW; Lee TY
J Clin Med; 2022 Mar; 11(5):. PubMed ID: 35268535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
